Anil R Maharaj1, Daniel Gonzalez2, Michael Cohen-Wolkowiez3,4, Christoph P Hornik3,4, Andrea N Edginton5. 1. School of Pharmacy, University of Waterloo, 10A Victoria St. S, Kitchener, ON, Canada. 2. Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3. Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA. 4. Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. 5. School of Pharmacy, University of Waterloo, 10A Victoria St. S, Kitchener, ON, Canada. aedginto@uwaterloo.ca.
Abstract
BACKGROUND: Differences in plasma protein levels observed between children and adults can alter the extent of xenobiotic binding in plasma, resulting in divergent patterns of exposure. OBJECTIVE: This study aims to quantify the ontogeny of α1-acid glycoprotein in both healthy and infected subjects. METHODS: Data pertaining to α1-acid glycoprotein from healthy subjects were compiled over 26 different publications. For subjects diagnosed or suspected of infection, α1-acid glycoprotein levels were obtained from 214 individuals acquired over three clinical investigations. The analysis evaluated the use of linear, power, exponential, log-linear, and sigmoid E max models to describe the ontogeny of α1-acid glycoprotein. Utility of the derived ontogeny equation for estimation of pediatric fraction unbound was evaluated using average-fold error and absolute average-fold error as measures of bias and precision, respectively. A comparison to fraction unbound estimates derived using a previously proposed linear equation was also instituted. RESULTS: The sigmoid E max model provided the comparatively best depiction of α1-acid glycoprotein ontogeny in both healthy and infected subjects. Despite median α1-acid glycoprotein levels in infected subjects being more than two-fold greater than those observed in healthy subjects, a similar ontogeny pattern was observed when levels were normalized toward adult levels. For estimation of pediatric fraction unbound, the α1-acid glycoprotein ontogeny equation derived from this work (average fold error 0.99; absolute average fold error 1.24) provided a superior predictive performance in comparison to the previous equation (average fold error 0.74; absolute average fold error 1.45). CONCLUSION: The current investigation depicts a proficient modality for estimation of protein binding in pediatrics and will, therefore, aid in reducing uncertainty associated with pediatric pharmacokinetic predictions.
BACKGROUND: Differences in plasma protein levels observed between children and adults can alter the extent of xenobiotic binding in plasma, resulting in divergent patterns of exposure. OBJECTIVE: This study aims to quantify the ontogeny of α1-acid glycoprotein in both healthy and infected subjects. METHODS: Data pertaining to α1-acid glycoprotein from healthy subjects were compiled over 26 different publications. For subjects diagnosed or suspected of infection, α1-acid glycoprotein levels were obtained from 214 individuals acquired over three clinical investigations. The analysis evaluated the use of linear, power, exponential, log-linear, and sigmoid E max models to describe the ontogeny of α1-acid glycoprotein. Utility of the derived ontogeny equation for estimation of pediatric fraction unbound was evaluated using average-fold error and absolute average-fold error as measures of bias and precision, respectively. A comparison to fraction unbound estimates derived using a previously proposed linear equation was also instituted. RESULTS: The sigmoid E max model provided the comparatively best depiction of α1-acid glycoprotein ontogeny in both healthy and infected subjects. Despite median α1-acid glycoprotein levels in infected subjects being more than two-fold greater than those observed in healthy subjects, a similar ontogeny pattern was observed when levels were normalized toward adult levels. For estimation of pediatric fraction unbound, the α1-acid glycoprotein ontogeny equation derived from this work (average fold error 0.99; absolute average fold error 1.24) provided a superior predictive performance in comparison to the previous equation (average fold error 0.74; absolute average fold error 1.45). CONCLUSION: The current investigation depicts a proficient modality for estimation of protein binding in pediatrics and will, therefore, aid in reducing uncertainty associated with pediatric pharmacokinetic predictions.
Authors: F Kanakoudi; V Drossou; V Tzimouli; E Diamanti; T Konstantinidis; A Germenis; G Kremenopoulos Journal: Clin Chem Date: 1995-04 Impact factor: 8.327
Authors: D J Malvy; J D Povéda; M Debruyne; B Montagnon; B Burtschy; C Herbert; P Cacès; O Houot; O Amédée-Manesme Journal: Clin Chem Date: 1992-03 Impact factor: 8.327
Authors: Daniel Gonzalez; Paula Delmore; Barry T Bloom; C Michael Cotten; Brenda B Poindexter; Elisabeth McGowan; Karen Shattuck; Kathleen K Bradford; P Brian Smith; Michael Cohen-Wolkowiez; Maurine Morris; Wanrong Yin; Daniel K Benjamin; Matthew M Laughon Journal: Antimicrob Agents Chemother Date: 2016-04-22 Impact factor: 5.938
Authors: Samuel J Reddick; Olivia Campagne; Jie Huang; Arzu Onar-Thomas; Alberto Broniscer; Amar Gajjar; Clinton F Stewart Journal: Cancer Chemother Pharmacol Date: 2019-08-07 Impact factor: 3.333
Authors: Kevin M Watt; Michael Cohen-Wolkowiez; Jeffrey S Barrett; Michael Sevestre; Ping Zhao; Kim L R Brouwer; Andrea N Edginton Journal: CPT Pharmacometrics Syst Pharmacol Date: 2018-08-13
Authors: Sara N Salerno; Andrea Edginton; Jacqueline G Gerhart; Matthew M Laughon; Namasivayam Ambalavanan; Gregory M Sokol; Chi D Hornik; Dan Stewart; Mary Mills; Karen Martz; Daniel Gonzalez Journal: Clin Pharmacol Ther Date: 2020-08-22 Impact factor: 6.903